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Over the past decade, there has been a
substantial increase globally in the cover-
age of effective interventions to reduce
morbidity and mortality from malaria.
Insecticide-treated bed nets (ITNs), indoor
residual spraying with insecticides, and the
use of more effective antimalarials have
been the cornerstones of such measures,
and there are now clear signs of a
sustained reduction in the burden of
malaria in many regions. However, fur-
ther interventions are urgently needed to
capitalise on recent progress and sustain
the malaria control and elimination effort.
Intermittent Preventive
Treatment of Malaria
One approach to help reduce the
burden of malaria caused by Plasmodium
falciparum is intermittent preventive treat-
ment (IPT), which involves periodic ther-
apeutic doses of antimalarials to reduce
the incidence of malaria and prevalence of
anemia [1,2]. Previous efforts to use
sustained chemoprophylaxis to prevent
malaria were complicated by drug toxicity
and safety concerns, promoting drug
resistance, rebound increases in malaria
once chemoprophylaxis ended, and logis-
tical challenges in implementing such an
intervention at the population level [3].
Instead, IPT seeks to balance these factors
by providing treatments that are frequent
enough to have significant benefit, without
the downsides of chemoprophylaxis. It
appears to act in part by post-treatment
prophylactic effects [4], while drug levels
remain above inhibitory concentrations;
long-acting drugs such as sulfadoxine-
pyrimethamine (SP) and amodiaquine
(AQ) have been widely used. IPT in
pregnancy (IPTp) reduces anemia and
low birth weight [5], and is now recom-
mended by the World Health Organiza-
tion (WHO) for all pregnant women at risk
in sub-Saharan Africa. IPT in infants
(IPTi) decreases malaria episodes by
22%–59% [6]. Since malaria is a major
cause of illness and death of children
under 5 years [7], recent studies have
evaluated the potential for using IPT
during childhood (known as IPTc) [8–
10], including three new papers in PLoS
Medicine that add to the growing evidence
base [11–13].
New Evidence for IPTc in the
Context of Established
Interventions
IPTc appears to be highly effective at
reducing clinical malaria episodes in
children under 5 with protective efficacy
against symptomatic malaria of 69% or
higher [8–10]. Two new trials add to our
understanding by studying the efficacy of
IPTc in the context of established inter-
ventions. These trials in Burkina Faso and
Mali, published in PLoS Medicine, now
show that the protective efficacy of IPTc
extends to children sleeping under ITNs
[11,12]. Both trials showed a high level of
protective efficacy against symptomatic
malaria (70% in Burkina Faso and 82%
in Mali), together with reductions in
moderately severe anaemia (56% and
48%, respectively) and severe malaria
(69% and 87%, respectively). All children
were given an ITN and were randomised
to receive three doses, at monthly inter-
vals, of SP plus AQ, or placebo, during the
transmission season. Previous IPTc trials,
in areas with seasonal peaks of transmis-
sion and low ITN use (,25%), have
achieved similar efficacies of 69% with
two doses of SP 8 weeks apart in Mali [9],
86% with three monthly doses of artesu-
nate (AS) plus AQ in Senegal [8], and
69% with six monthly doses of AS plus
AQ in Ghana [10]. Taken together, these
findings suggest that IPTc would provide a
valuable contribution in reducing malaria,
by itself or integrated with other interven-
tion strategies, in areas with highly sea-
sonal malaria.
New Evidence on the Delivery
of IPT in Children
Few studies have examined the most
efficacious and cost-effective means of
delivering IPTc. Unlike IPTi and IPTp,
which can be deployed as low-cost add-ons
to existing frameworks, namely EPI (Ex-
panded Program on Immunization) and
antenatal clinics, IPTc does not have a
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PLoS Medicine, Bojang et al. now report
important results from a randomised trial
of two different modes of delivery [13].
Their findings suggest greater effectiveness
in preventing symptomatic malaria when
delivered by village health workers
(VHWs) compared to reproductive and
child health (RCH) trekking clinics. Deliv-
ery by VHWs achieved superior coverage,
which was better sustained over the study
period, and appeared to be more cost
effective. The VHW arm had a tendency
towards increased ITN usage and greater
vaccination coverage. This further sup-
ports the important role of VHWs in
malaria control in addition to delivering
other health services to their communities,
and broadly argues in favour of strong
primary health care services in communi-
ties. While this model is potentially
transferrable to other populations, each
country considering IPTc implementation
will face its own logistic considerations, in
identifying, training, resourcing, and re-
warding providers of IPTc.
Successful implementation of IPTc in
different populations will need tailored
drug selection that considers safety, toler-
ability, drug half-life, and cost, and specific
regional circumstances, such as local
patterns of drug resistance. Currently,
SP/AQ appear to be favoured due to
tolerability, efficacy, and affordability, but
resistance to these drugs has reached
alarming levels in many regions. Indeed,
there was some evidence that markers of
drug resistance increased in recent trials
[11,12], which probably reflects selection
of pre-existing drug resistance; this may
compromise the long term efficacy of these
drugs. Presently, alternatives to SP and
AQ are very limited. Because of the
concerns over promoting drug resistance,
it is preferable to use drugs in IPTc that
are not used as first line for the treatment
of malaria cases. The use of SP for
treatment of malaria is being phased out
in many countries, which may reduce the
pressure for drug resistance.
The clinical benefit of IPTc in these
recent studies indicates that implementa-
tion over a longer period of childhood
would be appropriate. Administering IPTc
for several years may have a substantial
impact on acquired immunity such that a
rebound in malaria may be a problem
after IPTc ceases. At present, IPTc has
been trialled as a short-term intervention
(given during one season), and rebound
was not observed [8]. The lifetime benefit
of IPTc is likely to outweigh problems with
rebound, and this potential problem
should not be a barrier to implementing
IPTc. Nevertheless, it will be important to
anticipate and monitor these effects and
consider how they might be mitigated.
In What Settings Can IPTc Be
Used?
With strong evidence that IPTc is
effective in regions experiencing highly
seasonal malaria, it remains to be deter-
mined at what level of malaria transmis-
sion and seasonality IPTc can be justified.
It is also unclear how these factors should
influence the age at which IPTc should be
ceased. Determining the transmission level
at which IPTc should be implemented, or
continued in settings where malaria is
declining, is an important priority. Simi-
larly, the benefit of IPTc and how
frequently it should be given in regions
with extended malaria seasons or year-
round transmission, or in populations
outside Africa, is presently not clear.
Studies to date have targeted P. falciparum,
the major cause of malaria in Africa.
However, in many regions Plasmodium vivax
is an important cause of malaria, and
further studies may be warranted to
investigate whether IPTc could be used
for this. The added complexity is that P.
vivax has a dormant liver stage; clearing
blood-stage parasites will not prevent
further malaria, even in the absence of
re-exposure.
Conclusions
Based on the present evidence, we
support the call for the implementation
of IPTc as a population-level intervention
in specific settings to reduce the burden
of malaria in children. However, there is
still much we need to know about when,
how, and under what circumstances to
implement IPTc and how to mitigate
the potential impact of increasing drug
resistance and impairing immune acquisi-
tion. These questions need to be a high
priority for ongoing research, not only for
IPTc, but alongside other interventions
in a multi-faceted approach to malaria
control.
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Linked Research Articles
This Perspective discusses the following new studies published in PLoS Medicine:
1. Dicko A, Diallo AI, Tembine I, Dicko Y, Dara N, et al. (2011) Intermittent
Preventive Treatment of Malaria Provides Substantial Protection against Malaria in
Children Already Protected by an Insecticide-Treated Bednet in Mali: A
Randomised, Double-Blind, Placebo-Controlled Trial. PLoS Med 8(2): e1000407.
doi:10.1371/journal.pmed.1000407.
A randomized trial reported by Alassane Dicko and colleagues shows that
intermittent preventive treatment for malaria in children who are protected from
mosquitoes using insecticide-treated bednets provides substantial protection
from malaria.
2. Konate ´ AT, Yaro JB, Oue ´draogo AZ, Diarra A, Gansane ´ A, et al. (2011)
Intermittent Preventive Treatment of Malaria Provides Substantial Protection
against Malaria in Children Already Protected by an Insecticide-Treated Bednet in
Burkina Faso: A Randomised, Double-Blind, Placebo-Controlled Trial. PLoS Med
8(2): e1000408. doi:10.1371/journal.pmed.1000408.
A randomized trial reported by Diadier Diallo and colleagues shows that
intermittent preventive treatment for malaria in children who are protected from
mosquitoes using insecticide-treated bednets provides substantial protection
from malaria.
3. Bojang KA, Akor F, Conteh L, Webb E, Bittaye O, et al. (2011) Two Strategies for
the Delivery of IPTc in an Area of Seasonal Malaria Transmission in The Gambia: A
Randomised Controlled Trial. PLoS Med 8(2): e1000409. doi:10.1371/journal.pmed.
1000409.
Kalifa Bojang and colleagues report a randomized trial showing that delivery of
intermittent preventive treatment for malaria in children by village health workers
is more effective than delivery by reproductive and child health trekking clinics.
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